Salt Lake City, UT, United States of America

Warren S Weiner

This inventor holds 10 USPTO granted patents and 7 published patent applications and 4 EPO patents. Top assignees: University of Kansas, Myrexis, Inc., Myriad Pharmaceuticals, Inc.. Active years: 2010-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Warren S Weiner. Retrieved from https://idiyas.com/inventor/warren-s-weiner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

% Patents Active = 60.0

 

Average Co-Inventor Count = 7.8

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Salt Lake City, UT (US) (2010 - 2015)
  • Lawrence, KS (US) (2015)
  • Phoenix, AZ (US) (2015 - 2017)
  • Boston, MA (US) (2023)

Company Filing History:


Years Active: 2010-2024

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovations of Warren S. Weiner: A Pioneer in Selective Dopamine Receptor Agonists

Introduction

Warren S. Weiner is a prominent inventor based in Salt Lake City, Utah, recognized for his groundbreaking contributions to the field of pharmacology. With a notable portfolio comprising 10 patents, Weiner has made significant advancements, particularly in the development of selective dopamine receptor agonists, which have vast potential in treating various neurological disorders.

Latest Patents

Weiner's latest patents focus on innovative compounds related to selective D3 dopamine receptor agonists and their therapeutic applications. Among these patents, the disclosure of a compound of Formula I or a pharmaceutically acceptable salt highlights essential methods for treating a multitude of conditions. These conditions include Parkinson's disease, related syndromes, dyskinesia, and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease. Furthermore, the patents detail methods for addressing psychological conditions including bipolar disorder, depression, schizophrenia, and substance use disorders. The advanced compounds, along with pharmaceutically acceptable carriers, signify a major step forward in the medical field, offering hope for many patients suffering from these debilitating conditions.

Career Highlights

Weiner's career is marked by his affiliation with reputable institutions, including the University of Kansas, where his research has contributed to significant advancements in medical science. His extensive work in the development of dopamine receptor agonists has earned him recognition within the scientific community and among his peers.

Collaborations

Throughout his career, Weiner has collaborated with notable colleagues, including Mark B. Anderson and Rachel M. Slade. These partnerships have facilitated the pursuit of innovative solutions to complex medical challenges, further establishing Weiner's reputation as a leading inventor in his field.

Conclusion

Warren S. Weiner's contributions to the field of medicine not only showcase his innovative spirit but also reflect his commitment to improving patient outcomes through advanced therapeutic methods. With a strong foundation in research and collaboration, Weiner continues to be a pivotal figure in the development of treatments for various neurological and psychological disorders, paving the way for future advancements in pharmacology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…